The biotechnology-value chain: Development of Sm14 as a schistosomiasis vaccine
Authors:
- Miriam TendlerMTMiriam Tendler
- Andrew J.G. SimpsonASAndrew J.G. Simpson
- 1 November 2008
- journal article
- review article
- Published by Elsevier in Acta Tropica
- Vol. 108 (2-3) , 263-266
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at riskThe Lancet Infectious Diseases, 2006
- Reassessment of the cost of chronic helmintic infection: a meta-analysis of disability-related outcomes in endemic schistosomiasisThe Lancet, 2005
- Vaccine-linked chemotherapy: can schistosomiasis control benefit from an integrated approach?Trends in Parasitology, 2005
- An experimental bivalent peptide vaccine against schistosomiasis and fascioliasisVaccine, 2003
- Gene Structure and M20T Polymorphism of theSchistosoma mansoni Sm14 Fatty Acid-binding ProteinJournal of Biological Chemistry, 2003
- r-Sm14 - pRSETA efficacy in experimental animalsMemórias do Instituto Oswaldo Cruz, 2001
- CD4+ T Cells of Schistosomiasis Naturally Resistant Individuals Living in an Endemic Area Produce Interferon‐γ and Tumour Necrosis Factor‐α in Response to The Recombinant 14kdaSchistosoma mansoni Fatty Acid‐Binding ProteinScandinavian Journal of Immunology, 2000
- Schistosomiasis Vaccine:Research to DevelopmentParasitology Today, 1998
- Schistosomiasis Japonica in the Philippines: The Long-Term Impact of Population-Based Chemotherapy on Infection, Transmission, and MorbidityThe Journal of Infectious Diseases, 1996
- A Schistosoma mansoni fatty acid-binding protein, Sm14, is the potential basis of a dual-purpose anti-helminth vaccine.Proceedings of the National Academy of Sciences, 1996